NFlection is a biopharmaceutical company focused on the development of novel therapies to address the needs of patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks such as keratinocytic epidermal nevi.
To address these RAS-mediated disorders, driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway, we are developing first-in-class MEK (mitogen-activated protein kinase kinase) inhibitors as topical treatments.
Company Details
- Employees
- 9
- Address
- Boston, Ma, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.nflection.com/
- Keywords
- Wheaton.
- HQ
- Boston, MA
Nflection Therapeutics Questions
Nflection Therapeutics's website is https://www.nflection.com/
Nflection Therapeutics's LinkedIn profile is https://www.linkedin.com/company/nflection
Nflection Therapeutics has
9 employees.
View email and phone details for 9
employees at Nflection Therapeutics.
Nflection Therapeutics's industry is
Biotechnology Research
Nflection Therapeutics's top competitors are
Neurofibromatosis Network,
Children's Tumor Foundation,
Escient Pharmaceuticals,
Lyell Immunopharma,
Alexion Pharmaceuticals, Inc.,
Moderna,
Atai Life Sciences,
Jazz Pharmaceuticals,
Pentixapharm Ag,
Trypto Therapeutics.
Nflection Therapeutics's categories are Biotechnology Research
